Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Neurofibrosarcoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

NTRK1 fusion	Neurofibrosarcoma	NTRK1 fusion	Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Neurofibrosarcoma	NTRK3 fusion	Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
BRAF V600E	Neurofibrosarcoma	BRAF V600E	Neurofibrosarcoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
MTAP deletion	Neurofibrosarcoma	MTAP deletion	Neurofibrosarcoma	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3
TJP1-ROS1 fusion + NF1 mutation	Neurofibrosarcoma	TJP1-ROS1 fusion + NF1 mutation	Neurofibrosarcoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP Sensitive: D – Preclinical DR6MP Sensitive : D	DR6MP Sensitive: D – Preclinical DR6MP Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical MEK inhibitor + c-MET inhibitor Sensitive : D	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical MEK inhibitor + c-MET inhibitor Sensitive : D
TP53 mutation	Neurofibrosarcoma	TP53 mutation	Neurofibrosarcoma	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D